BrandWikiReturn

Shionogi

Shionogi & Company, Limited (塩野義製薬株式会社) is a Japanese pharmaceutical company best known for developing Crestor. Medical supply and brand name also uses katakana (シオノギ).

Shionogi has business roots that date back to 1878, and was incorporated in 1919. Among the medicines produced are for hyperlipidaemia, antibiotics, and cancer medicines.

In Japan it is particularly known as a producer of antimicrobial and antibiotics. Because of antibiotic resistance and slow growth of the antibiotic market, it has teamed up with US based Schering-Plough (merged in 2009 with Merck & Co) to become a sole marketing agent for its products in Japan.

Shionogi had supported the initial formation of Ranbaxy Pharmaceuticals, a generic manufacturer based in India. In 2012 the company became a partial owner of ViiV Healthcare, a pharmaceutical company specialising in the development of therapies for HIV.[4]

The company is listed on the Tokyo Stock Exchange and Osaka Securities Exchange and is constituent of the Nikkei 225 stock index.[5]

In June 2023, Shionogi announced its acquisition of Qpex Biopharma for approximately $140m.[6]

Medicines

Released

  • Avelox, antibacterial antiseptic that treats a number of infections.
  • Claritin, An anti-histamine marketed in alliance with Schering-Plough.
  • Crestor, cholesterol drug [[Image:Shionogi.JPG|thumb|right|Shionogi Headquarters in Osaka|315x315px]], marketing rights sold to AstraZeneca in 1998.[7][8]
  • Cymbalta, an SNRI class anti-depressant, marketed in alliance with Eli Lilly.
  • Differin (developed by Galderma), a topical retinoid for acne, marketed in Japan in alliance with Galderma.
  • Fortamet
  • Methylin
  • Mogadon, a short-term treatment for insomnia.
  • Mulpleta, a thrombopoietin receptor agonist.
  • Osphena, an estrogen receptor agonist, marketing rights sold to Duchesnay in 2017.[9]
  • Symproic, a μ-opioid receptor antagonist, for opioid-induced constipation treatment.
  • Xofluza, an endonuclease inhibitor, for influenza treatment.
  • Ensitrelvir, the first Japanese domestic pill to treat COVID-19.[10]

Under development

  • Asapiprant (BGE-175), a DP1 receptor antagonist under development for treatment of COVID-19 in elderly patients and allergic rhinitis.[11][12][13][14][15]

Media

  • Shionogi (and later Shinonogi Healthcare) has been the sponsor of Fuji Television Network, Inc.'s "Music Fair" since it started in 1964. In January 2025, Shionogi has decided to remove its name from the show, due to the Fuji TV - Masahiro Nakai scandal. A Shionogi representative said in an interview, "I believe that Fuji Television should provide an explanation of the facts and future actions as soon as possible".[16][17]
  • Shionogi was a main sponsor of Team Lotus in the team's final years between 1991 and 1994.[18]

External links

References

  1. Shionogi Company Profile retrieved March 18, 2014^
  2. Shionogi Annual Report 2013 retrieved March 18, 2014^
  3. Consolidated Financial Results for Fiscal Year 2022 (IFRS) 23 February 2023, retrieved 27 June 2023^
  4. Shionogi and ViiV Healthcare announce new agreement to commercialise and develop integrase inhibitor portfolio viivhealthcare.com, retrieved 18 March 2014^
  5. Components:Nikkei Stock Average Nikkei Inc., retrieved March 11, 2014^
  6. BioSpace. Shionogi buys Qpex Biopharma for $140M, expands antimicrobial pipeline – PharmaLive PharmaLive, 27 June 2023, retrieved 2023-06-27^
  7. Lisa Du. Covid Pill Sales Could Hit $2 Billion, Japan's Shionogi Says Bloomberg, 7 October 2021, retrieved 21 March 2022^
  8. Lisa Du. AstraZeneca begins court fight over Crestor patent Reuters, 22 February 2010, retrieved 21 March 2022^
  9. Duchesnay acquires Osphena from Shionogi Inc. Duchesnay, March 10, 2017, retrieved 23 October 2019^
  10. Japan's Shionogi seeks approval for COVID-19 pill Reuters, Reuters, 25 February 2022^
  11. Notice regarding an initiation of Phase 2 clinical trial by BioAge aimed at treating older patients of COVID-19 retrieved 2022-03-21^
  12. Study to Evaluate the Safety, Tolerability, and Efficacy of BGE-175 in Hospitalized Adults With Coronavirus Disease 2019 (COVID-19) That Are Not in Respiratory Failure ClinicalTrials.gov, retrieved 2022-03-21^
  13. Lok-Yin Wong. Eicosanoid signaling blockade protects middle-aged mice from severe COVID-19 Nature, 21 March 2022^
  14. Rocky Swift. Japan's Shionogi sells coronavirus drug rights to U.S. biotech BioAge 26 January 2021^
  15. New BioAge Drug Prevents Death From COVID-19 in Old Mice by Reversing Immune Aging BioAge Labs, retrieved 2022-03-21^
  16. [naka kōka] continúa la crisis en Fuji TV Noticias Nippon, 22 January 2025, retrieved 22 January 2025^
  17. 塩野義、番組から社名削除を検討 フジのミュージックフェア Nordot, 21 January 2025, retrieved 22 January 2025^
  18. Alan Perry. Sponsor Company Profiles retrieved 25 April 2012^